Heron Therapeutics Files 2024 10-K
Ticker: HRTX · Form: 10-K · Filed: 2025-02-27T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, pharmaceuticals, annual-report
TL;DR
Heron Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Heron Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as AP Pharma Inc. and Advanced Polymer Systems Inc., is based in San Diego, CA. The filing details its business operations in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Heron Therapeutics' financial performance, strategic initiatives, and risk factors for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Heron Therapeutics faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 20241231 — Fiscal Year End (The reporting period for the 10-K filing.)
- 20250227 — Filing Date (The date Heron Therapeutics submitted its 10-K.)
Key Players & Entities
- HERON THERAPEUTICS, INC. /DE/ (company) — Filer
- AP PHARMA INC /DE/ (company) — Former Company Name
- ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former Company Name
- 20241231 (date) — Fiscal Year End
- 20250227 (date) — Filing Date
- SAN DIEGO, CA (location) — Business Address
FAQ
What were Heron Therapeutics' primary revenue drivers in fiscal year 2024?
The 10-K filing would detail specific product revenues and any licensing or royalty income, but this summary does not contain that level of detail.
What are the key research and development activities Heron Therapeutics is pursuing?
The filing mentions 'ResearchAndDevelopmentExpense' but does not specify the particular drugs or therapeutic areas under development.
Did Heron Therapeutics announce any significant acquisitions or divestitures in 2024?
This filing is a 10-K for the fiscal year ending 2024 and does not explicitly mention acquisitions or divestitures in the provided header information.
What is Heron Therapeutics' current cash position as of December 31, 2024?
The provided header information does not include specific financial figures like cash on hand.
What are the main risks highlighted by Heron Therapeutics for the upcoming fiscal year?
While the filing is a 10-K, the specific risks are not detailed in the provided header information, though general pharmaceutical risks are implied.
From the Filing
0000950170-25-028374.txt : 20250227 0000950170-25-028374.hdr.sgml : 20250227 20250227074525 ACCESSION NUMBER: 0000950170-25-028374 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 25673074 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 10-K 1 hrtx-20241231.htm 10-K 10-K FY HERON THERAPEUTICS, INC. /DE/ 0000818033 false http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember http://www.herontx.com/20241231#CompanyCheifExecutiveOfficerMember http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202307Member 5 http://fasb.org/us-gaap/2024#SellingAndMarketingExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#SellingAndMarketingExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#ResearchAndDevelopmentExpense http://fasb.org/us-gaap/2024#SellingAndMarketingExpense http://fasb.org/us-gaap/2024#GeneralAndAdministrativeExpense 0000818033 2021-12-31 0000818033 hrtx:HerculesCapitalIncMember us-gaap:SubsequentEventMember 2025-02-13 2025-02-13 0000818033 us-gaap:OtherNoncurrentLiabilitiesMember 2024-12-31 0000818033 hrtx:SignificantCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0000818033 hrtx:ExercisePriceRange6Member 2024-12-31 0000818033 us-gaap:WarrantMember 2022-01-01 2022-12-31 0000818033 us-gaap:StateAndLocalJurisdictionMember 2024-01-01 2024-12-31 0000818033 hrtx:ForeignCommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000818033 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000818033 hrtx:ForeignCommercialPaperMember 2023-12-31 0000818033 hrtx:PreFundedWarrantMember 2022-08-08 0000818033 hrtx:TrancheOneBMember hrtx:HerculesCapitalIncMember 2023-08-15 0000818033 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-12-31 0000818033 us-gaap:CommonStockMember 2024-12-31 0000818033 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000818033 hrtx:HerculesCapitalIncMember hrtx:TrancheOneAMember 2023-01-01 2023-12-31 0000818033 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember hrtx:ThirdLargestCustomerMember 2022-01-01 2022-12-31 0000818033 us-gaap:RetainedEarningsMember 2021-12-31 0000818033 us-gaap:ForeignCorporateDebtSecuritiesMember 2023-12-31 0000818033 us-gaap:FairValueMeasurementsRecurringMember hrtx:UnitedStatesCommercialPaperMember 2023-12-31 0000818033 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0000818033 hrtx:ZYNRELEFMember 2022-01-01 2022-12-31 0000818033 hrtx:EmployeeStockPurchasePlanMember 2023-06-01 2023-06-30 0000818033 us-gaap:DomesticCorporateDebtSecuritiesMember 2024-12-31 0000818033 us-gaap:FurnitureAndFixturesMember 2024-12-31 0000818033 hrtx:EquityIncentivePlan2007Member 2023-06-01 2023-06-30 0000818033 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0000818033 stpr:CA 2022-01-01 2022-12-31 0000818033 stpr:CA 2021-10-31 0000818033 hrtx:ExercisePriceRange3Member 2024-12-31 0000818033 hrtx:ExercisePriceRange7Member 2024-01-01 2024